

Aegerion publishes Phase 3 results of cholesterol drug

Mass High Tech: The Journal of New England Technology

Data from a Phase 3 trial of a cholesterol-lowering drug candidate developed by Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) was published in an online medical journal Friday, two weeks after an advisory committee of the U.S. Food and Drug Administration voted favorably to approve it.

Source URL (retrieved on 01/30/2015 - 4:59pm):

<http://www.mdtmag.com/news/2012/11/aegerion-publishes-phase-3-results-cholesterol-drug>